GAMMAGARD LIQUID is a ready-to-use liquid medicine that is given in a vein (intravenously) or under the skin (subcutaneously) to treat primary immunodeficiency (PI) in people 2 years and older.
What to know about GAMMAGARD LIQUID
In the clinical study to look at the safety and effectiveness of GAMMAGARD LIQUID subQ, 47 patients with primary immunodeficiency (PI) were treated for about 1 year (54 weeks on average, with a range of 8 to 68 weeks overall). Patients receiving GAMMAGARD LIQUID showed protection against infection.
*A patient-year is a patient experience in a clinical trial over the course of 1 year.
†Validated acute serious bacterial infection (ASBI).
‡3 patients had pneumonia, which didn’t need hospitalization.
Of the 348 non-serious side effects reported in patients treated with subQ GAMMAGARD LIQUID, 228 were considered mild and 112 moderate. The remaining 8 were severe.
In 55 out of 2,294 infusions, side effects at the injection site were reported, including mild or moderate pain, swelling, itching, redness, bruising, and/or warmth.
Side effects may occur with a subQ treatment. The most common side effects in the trial with subQ infusions of GAMMAGARD LIQUID seen in ≥5% of patients were reactions at the infusion site, headache, fatigue, increased heart rate, fever, upper abdominal pain, nausea, vomiting, asthma, increased blood pressure, diarrhea, ear pain, canker sores, migraine, sore throat, and pain in the hands or feet.
When giving yourself infusions at home, you should have another responsible person present to help treat side effects or get help if a serious adverse reaction should occur. Ask your doctor whether you should have rescue medications on hand, like antihistamines or epinephrine, and what to expect with subQ infusions.
*After a few training sessions with a nurse.